Chiron Will Not Supply BEGRIVAC(TM) Influenza Virus Vaccine to Non-U.S. Markets for the 2005-2006 Influenza Season; Company is Working to Cover BEGRIVAC Vaccine Shortfall with Other Non-U.S. Influenza Vaccines.EMERYVILLE, Calif. -- No Change to Financial Guidance Chiron Corporation Chiron Corporation was a multinational biotechnology firm based in Emeryville, California that was acquired by Novartis International AG on April 20 2006. It had offices and facilities in eighteen countries on five continents. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CHIR CHIR Chiricahua National Monument (US National Park Service) ) today announced that further testing has confirmed the company will not be able to supply any BEGRIVAC(TM) influenza virus vaccine influenza virus vaccine n. A vaccine containing influenza virus, usually several strains of the virus, prepared in chick embryos and used to immunize against influenza. doses to non-U.S. markets during the 2005-2006 influenza season. There are no other changes from the company's previous announcement on July 15, 2005, on the same subject. About Chiron Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information, please visit www.chiron.com. This news release contains forward-looking statements, including statements regarding supply of BEGRIVAC(TM) influenza virus vaccine and other influenza virus vaccines that Chiron expects to deliver to non-U.S. markets, and assumptions regarding supply of FLUVIRIN(R) influenza virus vaccine that Chiron expects to deliver to the U.S. market, in future influenza seasons, sales and earnings expectations and improvements to manufacturing facilities, that involve risks and uncertainties and are subject to change. A discussion of the company's operations and financial condition, including factors that may affect its business and future prospects that could cause actual results and developments to differ materially from those expressed or implied by forward-looking statements, is contained in documents the company has filed with the SEC, including the Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2004, and the Form 10-Q Form 10-Q See 10-Q. for the quarter ended March 31, 2005, and will be contained in all subsequent periodic filings made with the SEC. These documents identify important factors that could cause the company's actual performance to differ from current expectations, including, among others, additional adverse developments resulting from the suspension of Chiron's UK license to manufacture FLUVIRIN vaccine from October 5, 2004, through March 2, 2005, the announcement of such suspension and the litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and investigations relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc those matters, the outcome of clinical trials, regulatory review and approvals, manufacturing capabilities, intellectual property protections and defenses, litigation, stock-price and interest-rate volatility, marketing effectiveness Marketing Effectiveness is the function of improving how marketers go to market with the goal of optimizing their marketing spend to achieve even better results for both the short-term and long-term. Also related to Marketing ROI and Return on Marketing Investment (ROMI). , and the severity of the 2005-2006 influenza season. In particular, there can be no assurance that additional issues with respect to the BEGRIVAC or FLUVIRIN vaccines or Chiron's manufacturing generally will not arise in the future, or that Chiron will be able to cover vaccine shortfalls, or will successfully address matters raised in a warning letter from the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) with respect to its FLUVIRIN vaccine manufacturing facility or resume sale of FLUVIRIN vaccine for the 2005-2006 influenza season or BEGRIVAC vaccine for the 2006-2007 influenza season. In addition, the company may face additional competition in the influenza market in the future and challenges in distribution arrangements as a result of the recent BEGRIVAC and FLUVIRIN vaccine developments. In addition, the company may engage in business opportunities, the successful completion of which is subject to certain risks, including approval by Novartis AG, shareholder and regulatory approvals, and the integration of operations. Chiron does not undertake an obligation to update the forward-looking information the company is giving today. NOTE: BEGRIVAC and FLUVIRIN are trademarks of Chiron Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion